Phase 2 vs Phase 3 — Neurology Deal Valuation Comparison

Phase 2 Median Upfront

$343M

Total: $3.0B

Phase 3 Median Upfront

$770M

Total: $4.1B

Stage Premium

33%

Phase 3 premium over Phase 2

Phase 2 Royalties

12.4%-19.8%

vs Phase 3: 16.1%-24.7%

Model Your Deal

Market Analysis

The Phase 2 to Phase 3 transition in neurology represents a significant value inflection point. Phase 3 deals carry a median total deal value of $4.1B compared to $3.0B at Phase 2, a 33% premium reflecting clinical de-risking. Upfront payments increase from $343M to $770M.

Deal structures shift as assets advance. Phase 2 deals allocate 11% to upfront and 89% to milestones, while Phase 3 deals shift to 19%/81%. Development milestones move from $890M to $492M, and royalty rates evolve from 12.4%-19.8% to 16.1%-24.7%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 2 to Phase 3 in neurology?

Phase 3 neurology deals command a 33% premium over Phase 2 in total deal value ($4.1B vs $3.0B). Upfronts increase from $343M to $770M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 2 and Phase 3 in neurology?

Phase 2 deals are more milestone-weighted (89% milestones), reflecting higher clinical risk. Phase 3 deals shift toward higher upfront allocations (19% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a neurology asset?

The optimal licensing window depends on strategic priorities. Phase 2 assets offer lower entry cost for licensees, while Phase 3 assets provide more certainty. The 33% premium from Phase 2 to Phase 3 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough